NASDAQ:PBYI

Puma Biotechnology Competitors

$10.07
-0.14 (-1.37 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.87
Now: $10.07
$10.25
50-Day Range
$9.33
MA: $10.27
$11.58
52-Week Range
$7.48
Now: $10.07
$14.14
Volume359,603 shs
Average Volume377,869 shs
Market Capitalization$405.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.39

Competitors

Puma Biotechnology (NASDAQ:PBYI) Vs. ADCT, HRMY, GBIO, AUPH, QURE, and TVTX

Should you be buying PBYI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Puma Biotechnology, including ADC Therapeutics (ADCT), Harmony Biosciences (HRMY), Generation Bio (GBIO), Aurinia Pharmaceuticals (AUPH), uniQure (QURE), and Travere Therapeutics (TVTX).

Puma Biotechnology (NASDAQ:PBYI) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Puma Biotechnology and ADC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Puma Biotechnology-23.86%-451.50%-22.80%
ADC TherapeuticsN/AN/AN/A

Insider and Institutional Ownership

87.9% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are owned by institutional investors. 21.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Puma Biotechnology and ADC Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$272.30 million1.49$-75,600,000.00($1.95)-5.16
ADC Therapeutics$2.34 million685.68$-116,480,000.00($2.36)-9.87

Puma Biotechnology has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Puma Biotechnology and ADC Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Puma Biotechnology14102.00
ADC Therapeutics01402.80

Puma Biotechnology presently has a consensus price target of $12.50, suggesting a potential upside of 24.13%. ADC Therapeutics has a consensus price target of $47.50, suggesting a potential upside of 103.95%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Puma Biotechnology.

Summary

ADC Therapeutics beats Puma Biotechnology on 7 of the 13 factors compared between the two stocks.

Puma Biotechnology (NASDAQ:PBYI) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

87.9% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 21.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Puma Biotechnology and Harmony Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$272.30 million1.49$-75,600,000.00($1.95)-5.16
Harmony BiosciencesN/AN/AN/AN/AN/A

Harmony Biosciences has lower revenue, but higher earnings than Puma Biotechnology.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Puma Biotechnology and Harmony Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Puma Biotechnology14102.00
Harmony Biosciences00303.00

Puma Biotechnology presently has a consensus price target of $12.50, suggesting a potential upside of 24.13%. Harmony Biosciences has a consensus price target of $51.6667, suggesting a potential upside of 83.54%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than Puma Biotechnology.

Profitability

This table compares Puma Biotechnology and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Puma Biotechnology-23.86%-451.50%-22.80%
Harmony BiosciencesN/AN/AN/A

Summary

Harmony Biosciences beats Puma Biotechnology on 6 of the 9 factors compared between the two stocks.

Puma Biotechnology (NASDAQ:PBYI) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

87.9% of Puma Biotechnology shares are held by institutional investors. Comparatively, 63.3% of Generation Bio shares are held by institutional investors. 21.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Puma Biotechnology and Generation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Puma Biotechnology-23.86%-451.50%-22.80%
Generation BioN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Puma Biotechnology and Generation Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Puma Biotechnology14102.00
Generation Bio00603.00

Puma Biotechnology presently has a consensus target price of $12.50, suggesting a potential upside of 24.13%. Generation Bio has a consensus target price of $40.60, suggesting a potential upside of 43.46%. Given Generation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Generation Bio is more favorable than Puma Biotechnology.

Valuation & Earnings

This table compares Puma Biotechnology and Generation Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$272.30 million1.49$-75,600,000.00($1.95)-5.16
Generation BioN/AN/AN/AN/AN/A

Generation Bio has lower revenue, but higher earnings than Puma Biotechnology.

Summary

Generation Bio beats Puma Biotechnology on 6 of the 9 factors compared between the two stocks.

Puma Biotechnology (NASDAQ:PBYI) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Puma Biotechnology and Aurinia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Puma Biotechnology-23.86%-451.50%-22.80%
Aurinia Pharmaceuticals-173,992.23%-36.98%-31.06%

Valuation and Earnings

This table compares Puma Biotechnology and Aurinia Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$272.30 million1.49$-75,600,000.00($1.95)-5.16
Aurinia Pharmaceuticals$320,000.004,918.81$-123,850,000.00($0.89)-13.88

Puma Biotechnology has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Puma Biotechnology and Aurinia Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Puma Biotechnology14102.00
Aurinia Pharmaceuticals01702.88

Puma Biotechnology currently has a consensus price target of $12.50, indicating a potential upside of 24.13%. Aurinia Pharmaceuticals has a consensus price target of $28.50, indicating a potential upside of 130.77%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Puma Biotechnology.

Insider and Institutional Ownership

87.9% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 51.2% of Aurinia Pharmaceuticals shares are owned by institutional investors. 21.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Puma Biotechnology has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Summary

Puma Biotechnology beats Aurinia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

uniQure (NASDAQ:QURE) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

78.3% of uniQure shares are held by institutional investors. Comparatively, 87.9% of Puma Biotechnology shares are held by institutional investors. 2.8% of uniQure shares are held by company insiders. Comparatively, 21.2% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares uniQure and Puma Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
uniQure-2,738.33%-59.64%-41.47%
Puma Biotechnology-23.86%-451.50%-22.80%

Valuation and Earnings

This table compares uniQure and Puma Biotechnology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$7.28 million210.57$-124,200,000.00($3.11)-10.95
Puma Biotechnology$272.30 million1.49$-75,600,000.00($1.95)-5.16

Puma Biotechnology has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

uniQure has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for uniQure and Puma Biotechnology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
uniQure011113.00
Puma Biotechnology14102.00

uniQure presently has a consensus target price of $68.4615, indicating a potential upside of 100.94%. Puma Biotechnology has a consensus target price of $12.50, indicating a potential upside of 24.13%. Given uniQure's stronger consensus rating and higher probable upside, analysts clearly believe uniQure is more favorable than Puma Biotechnology.

Summary

Puma Biotechnology beats uniQure on 9 of the 15 factors compared between the two stocks.

Travere Therapeutics (NASDAQ:TVTX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Volatility & Risk

Travere Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

Profitability

This table compares Travere Therapeutics and Puma Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
Puma Biotechnology-23.86%-451.50%-22.80%

Earnings & Valuation

This table compares Travere Therapeutics and Puma Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21
Puma Biotechnology$272.30 million1.49$-75,600,000.00($1.95)-5.16

Puma Biotechnology has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Travere Therapeutics and Puma Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00503.00
Puma Biotechnology14102.00

Travere Therapeutics presently has a consensus price target of $44.3333, indicating a potential upside of 77.69%. Puma Biotechnology has a consensus price target of $12.50, indicating a potential upside of 24.13%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Travere Therapeutics is more favorable than Puma Biotechnology.

Insider and Institutional Ownership

87.9% of Puma Biotechnology shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by company insiders. Comparatively, 21.2% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Puma Biotechnology beats Travere Therapeutics on 8 of the 14 factors compared between the two stocks.


Puma Biotechnology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29-1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15-0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30-2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35-2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07-4.1%$1.53 billion$7.28 million-9.04Insider Selling
Gap Down
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34News Coverage
Gap Down
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00Gap Up
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
Gap Down
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
Gap Down
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Gap Down
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Gap Down
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
News Coverage
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43-1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51-6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41-2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
News Coverage
Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.